Date: 2015-08-04
Type of information: Development agreement
Compound: prophylactic vaccine to protect against respiratory syncytial virus (RSV)
Company: Curevac (Germany) the Bill & Melinda Gates Foundation (USA)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism:
Disease: respiratory syncytial virus (RSV)
Details: * On August 4, 2015, CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, announced that the company has initiated its third target product development program in collaboration with the Bill & Melinda Gates Foundation. The program will leverage CureVac\'s RNActive® technology platform in the development of a prophylactic vaccine to protect against respiratory syncytial virus (RSV), adding to the development programs previously initiated by CureVac and the Gates Foundation targeting mRNA vaccines for HIV and Rotavirus. In March 2015, the Gates Foundation participated with $52 million in CureVac\'s financing round of a total of $76 million in the form of an equity investment to support continued development of CureVac\'s RNA technology platform and the construction of an industrial scale Good Manufacturing Practice (GMP) production facility. As part of this partnership, CureVac and the Gates Foundation anticipate that they will also collaborate on the development and production of numerous vaccines against infectious diseases that disproportionately affect people in the world\'s poorest countries. Under the terms of the agreement, any Gates Foundation funded products will be made available by CureVac at an affordable price in poor countries, while CureVac will be able to market such products in developed countries on its own, through licensees or a combination of both. In addition, the new manufacturing facility will have dedicated capacity to focus on products resulting from Gates Foundation-related projects.
Financial terms:
Latest news:
